Proteome biology of stem cells: a new joint HUPO and ISSCR initiative

Department of Biomolecular Mass Spectrometry, Utrecht University, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands.
Molecular &amp Cellular Proteomics (Impact Factor: 6.56). 02/2008; 7(1):204-5. DOI: 10.1074/mcp.H800001-MCP200
Source: PubMed
3 Reads
  • Source
    • "Both basic and clinically oriented stem cell research are confronted with many open questions that can be most efficiently answered by proteomics. For instance, the cell surface proteins and signaling cascades of stem cells and their differentiated progenies are largely unknown, as are the differentiation-specific proteins that can be used as biomarkers of the intermediate or terminal steps of cell differentiation, or discriminate tumorigenic cells from the pool (Krijgsveld et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stem cell research has been widely studied over the last few years and has attracted increasing attention from researchers in all fields of medicine due to its potential to treat many previously incurable diseases by replacing damaged cells or tissues. As illustrated by hematopoietic stem research, understanding stem cell differentiation at molecular levels is essential for both basic research and for clinical applications of stem cells. Although multiple integrative analyses, such as genomics, epigenomics, transcriptomics and proteomics, are required to understand stem cell biology, proteomics has a unique position in stem cell research. For example, several major breakthroughs in HSC research were due to the identification of proteins such as colony-stimulating factors (CSFs) and cell-surface CD molecules. In 2007, the Human Proteome Organization (HUPO) and the International Society for Stem Cell Research (ISSCR) launched the joint Proteome Biology of Stem Cells Initiative. A systematic proteomics approach to understanding stem cell differentiation will shed new light on stem cell biology and accelerate clinical applications of stem cells.
    Anatomy & cell biology 03/2010; 43(1):1-14. DOI:10.5115/acb.2010.43.1.1
  • Source

  • [Show abstract] [Hide abstract]
    ABSTRACT: Over 1000 patients have participated worldwide in clinical trials exploring the therapeutic value of bone marrow-derived cells in ischemic heart disease. Meta-analysis evaluation of this global effort indicates that adult stem cell therapy is in general safe, but yields a rather modest level of improvement in cardiac function and structural remodeling in the setting of acute myocardial infarction or chronic heart failure. Although promising, the potential of translating adult stem cell-based therapy from bench to bedside has yet to be fully realized. Inter-trial and inter-patient variability contribute to disparity in the regenerative potential of transplanted stem cells with unpredictable efficacy on follow-up. Strategies that mimic the natural embryonic program for uniform recruitment of cardiogenic progenitors from adult sources are currently tested to secure consistent outcome. Guided cardiopoiesis has been implemented with mesenchymal stem cells obtained from bone marrow of healthy volunteers, using a cocktail of secreted proteins that recapitulate components of the endodermal secretome critical for cardiogenic induction of embryonic mesoderm. With appropriate validation of this newly derived cardiopoietic phenotype, the next generation of trials should achieve demonstrable benefit across patient populations.
    Journal of Molecular and Cellular Cardiology 10/2008; 45(4-45):523-529. DOI:10.1016/j.yjmcc.2008.09.122 · 4.66 Impact Factor
Show more